News - Biocon

Filter

Current filters:

Biocon

Popular Filters

Mylan debuts Hertraz, first Herceptin biosimilar, in India

Mylan debuts Hertraz, first Herceptin biosimilar, in India

03-02-2014

US generics major Mylan has launched the world's first trastuzumab biosimilar in India. The product,…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazIndiaMarkets & MarketingMylan LaboratoriesOncologyRoche

India loses its attraction for pharma clinical trials, as domestic regulations tighten

India loses its attraction for pharma clinical trials, as domestic regulations tighten

27-01-2014

Considered a global clinical trial hub three years ago, India has suffered a series of setbacks, with…

Asia-PacificBioconIndiaPharmaceuticalPiramal HealthcareRegulationResearch

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

23-01-2014

Indian biotech firm Biocon has entered into an exclusive licensing agreement for US cancer drug developer…

AdvaxisADXS-HPVAsia-PacificBioconIndiaLicensingOncologyPharmaceuticalWomen's Health

Biocon introduces biosimilar trastuzumab for breast cancer in India

20-01-2014

India-based biotech firm Biocon (BSE: 532523) has introduced Canmab, a biosimilar trastuzumab, for the…

BioconBiosimilarsIndiaMarkets & MarketingOncologytrastuzumab

Biocon and Quark Pharma collaborate on novel siRNA based therapeutics

18-12-2013

India-based biotech firm Biocon and the USA’s Quark Pharmaceuticals have entered into a licensing and…

BioconBiotechnologyLicensingOphthalmicsQuark PharmaceuticalsResearch

Mylan-Biocon Herceptin biosimilar gets first Indian approval

Mylan-Biocon Herceptin biosimilar gets first Indian approval

26-11-2013

US generic major Mylan says that its partner, India-based biotechnology firm Biocon has received approval…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazMylan LaboratoriesOncologyRegulationRoche

First in class novel biologic for psoriasis launched in India

13-08-2013

Bangalore, India-based Biocon (BSE: 532523), Asia's premier biotechnology company, has launched its 'first…

ALZUMAbAsia-PacificBioconBiotechnologyDermatologicalsitolizumabMarkets & Marketing

Bristol-Myers Squibb signs option for Biocon's oral insulin drug candidate

19-11-2012

Bangalore, India-based biotechnology firm Biocon (BSE: 532523) has entered into an option agreement with…

BioconBiotechnologyBristol-Myers SquibbDiabetesIN-105LicensingPharmaceuticalResearch

Pfizer and Biocon cancel biosimilars deal

14-03-2012

Indian biotech firm Biocon (BSE: 532523) and global drugs behemoth Pfizer (NYSE: PFE) yesterday announced…

Asia-PacificBioconBiotechnologyDiabetesInsulinLicensingNovo NordiskPfizerPharmaceutical

Back to top